Opinion|Videos|July 30, 2024
Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC
Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you describe the current shortage of bacillus Calmette-Guerin, or BCG, therapy; how has this has impacted your clinical practice and management of high-risk NMIBC?
Advertisement
Related to this article
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Topline results from the study are anticipated in the first half of 2027.
The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Advertisement
Advertisement
Trending on Urology Times
1
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
2
LITESPARK-012: Lessons from a negative phase 3 trial in first-line RCC
3
ESMO 2026 recap: Notable updates across genitourinary oncology
4
Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
5